News and Trends 6 Sep 2024 Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection? Delve into the psychedelic-assisted therapy market and investors’ sentiment after the FDA’s decision about Lykos’ therapy. September 6, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 6 Sep 2024The power of tumor infiltrating lymphocytes to fight melanoma Listen to our conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline. September 6, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 5 Sep 2024 The biggest private biotech investments in August 2024 The companies Borealis Biosciences, Outpace Bio, and Halda Therapeutics bagged the biggest private biotech investments in August 2024. September 5, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Sep 2024 Six biotech companies that could revolutionize obesity treatments In this article, we take a look at six biotechs focused on bringing drugs to treat obesity to the market. September 5, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2024 2024: a year of breakthroughs for endometrial cancer? New treatments have been approved by regulators for endometrial cancer, which are regarded as major therapeutic breakthroughs. September 4, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 3 Sep 2024 Adaptimmune: The long road toward finally bringing the first TCR-T cell therapy to the market Find out about Adaptimmune’s long – and somewhat bumpy – road toward bringing the first TCR-T therapy to the market. September 3, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Sponsored by Lonza 3 Sep 2024 The crucial role of GS-CHO innovation in biopharmaceutical progress Learn how GS-CHO systems are advancing to improve yields and quality in biomanufacturing, meeting the rising need for effective therapeutic proteins. September 3, 2024 - 8 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2024 Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration Delve into the downturn AI is experiencing in biotech: Is the bubble bursting or is the market correcting the high expectations? September 2, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 30 Aug 2024The future of combination vaccines To look at combination vaccines, listen to our conversation with Cesar Sanz Rodriguez, vice president, Europe & Switzerland, medical affairs, at Moderna. August 30, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
News and Trends 28 Aug 2024 GLP-1 shortage: Can biotech companies keep up with rising demand? How is the biotech industry responding to the GLP-1 drug shortage? We asked experts in the field to answer this question. August 28, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 27 Aug 2024 Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential? As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond. August 27, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 23 Aug 2024New German biotech spins out to develop radiotherapeutics While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company August 23, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More